Ascendis Pharma
ASND

$151.26

1.41%

Market Cap: $8.67B

About: Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Employees: 879

0

Funds holding %

of 6,728 funds

0

Analysts bullish %

of 18 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

65% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 23

8% more funds holding

Funds holding: 185 [Q1] → 200 (+15) [Q2]

6% more funds holding in top 10

Funds holding in top 10: 16 [Q1] → 17 (+1) [Q2]

7% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 67

0.45% less ownership

Funds ownership: 105.39% [Q1] → 104.95% (-0.45%) [Q2]

10% less capital invested

Capital invested by funds: $9.19B [Q1] → $8.26B (-$934M) [Q2]

52% less call options, than puts

Call options by funds: $21.1M | Put options by funds: $43.9M

See Fund Rankings

Research analyst outlook

18 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$157

4%

upside

Avg. target

$192

27%

upside

High target

$289

91%

upside

18 analyst ratings

18 positive

100%

0 neutral

0%

0 negative

0%

Wells Fargo Derek Archila 69% 1-year accuracy 20 / 29 met price target	91%upside $289	Overweight Maintained	17 Sept 2024
Citigroup David Lebowitz 58% 1-year accuracy 11 / 19 met price target	37%upside $207	Buy Maintained	17 Sept 2024
Evercore ISI Group Josh Schimmer 65% 1-year accuracy 49 / 75 met price target	36%upside $205	Outperform Maintained	17 Sept 2024
Oppenheimer Leland Gershell 62% 1-year accuracy 31 / 50 met price target	26%upside $190	Outperform Reiterated	17 Sept 2024
Goldman Sachs Paul Choi 60% 1-year accuracy 6 / 10 met price target	32%upside $200	Buy Maintained	17 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 18 articles about ASND published over the past 30 days

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

COPENHAGEN, Denmark, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the pricing of its underwritten public offering of 2,000,000 American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis, at a price to the public of $150.00 per ADS. All of the ADSs are being offered by Ascendis. The offering is expected to close on or about September 23, 2024, subject to the satisfaction of customary closing conditions. In addition, Ascendis has granted the underwriters a 30-day option to purchase up to an additional 300,000 ADSs at the public offering price, less the underwriting commissions.

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

COPENHAGEN, Denmark, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has commenced an underwritten public offering of $300,000,000 of American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis. All of the ADSs are being offered by Ascendis. In addition, Ascendis expects to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of ADSs at the public offering price, less the underwriting commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the proposed offering.

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Zacks Investment Research

Ascendis Soars on Encouraging Data From Dwarfism Drug Study

ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal.

Ascendis Soars on Encouraging Data From Dwarfism Drug Study

Zacks Investment Research

Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?

Ascendis Pharma (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?

Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year

Ascendis Pharma A/S ASND released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and disproportionate short stature.

Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year

Investors Business Daily

Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug

Ascendis Pharma stock rocketed Monday on promising test results for a growth treatment that could rival BioMarin's approved drug, Voxzogo.

Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

– TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

COPENHAGEN, Denmark, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced initial data showing signs of clinical activity in heavily pre-treated patients with platinum-resistant ovarian cancer (PROC) treated with TransCon IL-2 β/γ in combination with chemotherapy in its ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 β/γ. First results will be shared in Poster 762P at ESMO 2024, the annual meeting of the European Society of Medical Oncology being held in Barcelona from September 13-17, 2024.

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

– U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for YORVIPATH in the United States for the treatment of hypoparathyroidism in adults

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma Takes A Big Price Cut On Skytrofa

Shares of Ascendis Pharma are under pressure as the company posted a big Q2 revenue miss, driven by a decision to significantly reduce the net price of Skytrofa. Demand for Skytrofa remains strong and quarterly net sales could go back to new highs in the fourth quarter, if not in Q3 already. Yorvipath's U.S. price is above expectations and could increase long-term sales, but initial uptake and payer pushback need monitoring.

Ascendis Pharma Takes A Big Price Cut On Skytrofa

See News Rankings